Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Filings indexed 958 across all filing types
Latest filing 2024-05-02 Director's Dealing
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
Director's Dealing 2024
Director's Dealing
2024-05-02 English
Director's Dealing 2024
Director's Dealing
2024-04-10 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated March 21, 2024. It reports the results of the 2024 annual meeting of stockholders, including voting results on director elections, executive compensation approval, and ratification of the independent auditor. The key section is Item 5.07, which is specifically about submission of matters to a vote of security holders. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document also includes a presentation used at the annual meeting, but the main content is the official voting results. The document length is 5772 characters, which is sufficient to contain detailed voting results, not just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2024-03-22 English
Director's Dealing 2024
Director's Dealing
2024-03-15 English
Director's Dealing 2024
Director's Dealing
2024-03-15 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Q1 2024
2024-03-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.